Niels WCJ van de Donk

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Diana Cortés‐Selva, Tineke Casneuf, Deeksha Vishwamitra et al. · Blood · 2022 · 46 citations

Life Sciences, Hematology, Immunology +17

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · Blood · 2022 · 42 citations

Medicine, Immunology, Pharmacotherapy +12

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Elena Zamagni, Mario Boccadoro, Andrew Spencer et al. · Blood · 2022 · 29 citations

Medicine, Oncology, Pharmacotherapy +14

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Niels WCJ van de Donk, Mounzer Agha, Adam D. Cohen et al. · Blood · 2022 · 26 citations

Medicine, Hematology, Oncology +17

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Hermann Einsele, J. San‐Miguel, Binod Dhakal et al. · The Lancet Oncology · 2026 · 26 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15